Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Atkins

Showing results (171-180 of 208) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08Carmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101Lawrence N Shulman, Constance T Cirrincione, Donald A Berry, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 25, 2018
Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance)Erin L Van Blarigan, Fang-Shu Ou, Donna Niedzwiecki, et al.
Journal of the National Cancer Institute|November 17, 2005
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyBernard Fisher, Joseph P Costantino, D Lawrence Wickerham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerCarmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Annals of Surgery|March 28, 2014
Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04Marcia M Russell, Patricia A Ganz, Samia Lopa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23B Fisher, S Anderson, E Tan-Chiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracilB Fisher, J Dignam, E P Mamounas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205Philip A Philip, Jacqueline Benedetti, Christopher L Corless, et al.
Journal of the National Cancer Institute|June 18, 2010
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerJudy E Garber, Susan Halabi, Sara M Tolaney, et al.
Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08Carmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101Lawrence N Shulman, Constance T Cirrincione, Donald A Berry, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 25, 2018
Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance)Erin L Van Blarigan, Fang-Shu Ou, Donna Niedzwiecki, et al.
Journal of the National Cancer Institute|November 17, 2005
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 studyBernard Fisher, Joseph P Costantino, D Lawrence Wickerham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancerCarmen J Allegra, Greg Yothers, Michael J O'Connell, et al.
Annals of Surgery|March 28, 2014
Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04Marcia M Russell, Patricia A Ganz, Samia Lopa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23B Fisher, S Anderson, E Tan-Chiu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracilB Fisher, J Dignam, E P Mamounas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205Philip A Philip, Jacqueline Benedetti, Christopher L Corless, et al.
Journal of the National Cancer Institute|June 18, 2010
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancerJudy E Garber, Susan Halabi, Sara M Tolaney, et al.
Pageof 21